Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$28.25
+0.5%
$26.51
$16.65
▼
$31.00
$1.24B0.93478,712 shs497,439 shs
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
$28.34
-3.9%
$35.39
$10.46
▼
$49.70
$4.13B2.231.61 million shs3.23 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.90
-0.1%
$13.78
$5.69
▼
$13.94
$3.65B1.534.91 million shs3.57 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$73.01
-6.0%
$74.22
$53.89
▼
$91.53
$3.60B0.34779,728 shs706,752 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-5.39%-2.63%+8.37%+30.14%+10.80%
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
+1.24%-10.67%-15.99%-34.36%+169.72%
Organon & Co. stock logo
OGN
Organon & Co.
0.00%+0.14%+1.16%+1.13%+86.65%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
+2.26%+1.01%+9.35%+6.84%+0.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$28.25
+0.5%
$26.51
$16.65
▼
$31.00
$1.24B0.93478,712 shs497,439 shs
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
$28.34
-3.9%
$35.39
$10.46
▼
$49.70
$4.13B2.231.61 million shs3.23 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.90
-0.1%
$13.78
$5.69
▼
$13.94
$3.65B1.534.91 million shs3.57 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$73.01
-6.0%
$74.22
$53.89
▼
$91.53
$3.60B0.34779,728 shs706,752 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-5.39%-2.63%+8.37%+30.14%+10.80%
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
+1.24%-10.67%-15.99%-34.36%+169.72%
Organon & Co. stock logo
OGN
Organon & Co.
0.00%+0.14%+1.16%+1.13%+86.65%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
+2.26%+1.01%+9.35%+6.84%+0.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1.88
Reduce$23.33-17.40% Downside
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
2.90
Moderate Buy$66.29133.92% Upside
Organon & Co. stock logo
OGN
Organon & Co.
1.80
Reduce$12.00-13.67% Downside
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2.80
Moderate Buy$104.5743.23% Upside

Current Analyst Ratings Breakdown

Latest AMPH, DFTX, TARS, and OGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
Boost Price TargetOverweight$84.00 ➝ $85.00
11/10/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
Boost Price TargetOutperform$66.00 ➝ $70.00
11/6/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Boost Price TargetEqual Weight$20.00 ➝ $25.00
11/5/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Boost Price TargetBuy$89.00 ➝ $97.00
11/4/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
UpgradeHold (C-) ➝ Hold (C)
11/4/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Boost Price TargetBuy$88.00 ➝ $106.00
10/19/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
Reiterated RatingOutperform
10/16/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
UpgradeSell (D+) ➝ Hold (C-)
10/15/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
Reiterated RatingSell (D-)
10/15/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Reiterated RatingSell (D-)
10/13/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
UpgradeStrong Sell ➝ Hold
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$719.89M1.67$4.12 per share6.86$19.10 per share1.48
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
N/AN/AN/AN/A$7.07 per shareN/A
Organon & Co. stock logo
OGN
Organon & Co.
$6.22B0.59$5.79 per share2.40$4.54 per share3.06
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$451.36M7.98N/AN/A$2.11 per share34.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$98.09M$2.1910.8810.825.6913.27%15.31%7.15%N/A
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
-$183.79M-$3.11N/AN/AN/AN/A-53.23%-43.90%N/A
Organon & Co. stock logo
OGN
Organon & Co.
$187M$0.7618.294.051.283.49%82.06%6.03%N/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$66.42M-$15.19N/A101.40N/A-102.93%-24.51%-12.40%N/A

Latest AMPH, DFTX, TARS, and OGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
-$0.55-$0.46+$0.09-$0.46N/AN/A
11/5/2026Q3 2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.8590$1.14+$0.2810$0.87$197.52 million$207.61 million
11/3/2026Q3 2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$1.46-$14.40-$12.94-$14.40$187.83 million$194.57 million
10/30/2026Q3 2026
Organon & Co. stock logo
OGN
Organon & Co.
$0.88$0.94+$0.06$0.60$1.58 billion$1.57 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.58%N/A10.53%N/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest AMPH, DFTX, TARS, and OGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/30/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.58%11/9/202611/9/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.75
3.32
2.36
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
0.04
15.53
15.53
Organon & Co. stock logo
OGN
Organon & Co.
7.11
2.02
1.51
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.70
1.96
1.94

Institutional Ownership

CompanyInstitutional Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
27.91%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1,97642.65 million30.03 millionOptionable
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
40136.90 million133.61 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000262.62 million258.37 millionOptionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
37049.31 million44.55 millionOptionable

Recent News About These Companies

Tarsus Pharmaceuticals (TARS) Stock Looks Cheap On Its 342% Run
Guggenheim Keeps Their Buy Rating on Tarsus Pharmaceuticals (TARS)
OC500 2026: BRYAN WAHL
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Tarsus (TARS) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$28.25 +0.14 (+0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$28.26 +0.01 (+0.04%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Definium Therapeutics stock logo

Definium Therapeutics NASDAQ:DFTX

$28.34 -1.14 (-3.87%)
As of 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.90 -0.01 (-0.07%)
Closing price 03:59 PM Eastern
Extended Trading
$13.80 -0.10 (-0.71%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$73.01 -4.66 (-6.00%)
Closing price 04:00 PM Eastern
Extended Trading
$71.83 -1.18 (-1.62%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.